GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration | Zendy

Qiang Zhou | Zendy; Junxia Zhang | Zendy; QINYING CUI | Zendy; Xiaodong Li | Zendy; Ge Gao | Zendy; Yanfen Wang | Zendy; Yuping Xu | Zendy; Xiaoqun Gao | Zendy

Open Access

GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration

Author(s) -

Qiang Zhou,

Junxia Zhang,

QINYING CUI,

Xiaodong Li,

Ge Gao,

Yanfen Wang,

Yuping Xu,

Xiaoqun Gao

Publication year - 2015

Publication title -

molecular medicine reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.727

H-Index - 56

eISSN - 1791-3004

pISSN - 1791-2997

DOI - 10.3892/mmr.2015.3869

Subject(s) - glioma , cancer research , cell cycle , apoptosis , insulin like growth factor , cell growth , oncogene , biology , cell , growth factor , signal transduction , receptor , microbiology and biotechnology , biochemistry

Malignant gliomas are the most common type of primary malignancy of the central nervous system, with a poor prognosis. The therapeutic options for malignant gliomas are limited and far from satisfactory, and novel treatment strategies are urgently required to improve the outcome of the disease. Insulin‑like growth factor (IGF)/IGF‑1 receptor (IGF‑1R) signaling pathway regulates cell proliferation, motility and survival. The dysregulation of this signaling pathway has been implicated in the development of malignant gliomas. In the present study, GSK1904529A, a small molecule inhibitor of IGF‑1R, suppressed glioma cell viability, induced glioma cell apoptosis and inhibited glioma cell migration in vitro. In addition, GSK1904529A inhibited glioma tumor growth and induced tumor cell apoptosis in vivo. In conclusion, the results of the present study suggested GSK1904529A as a promising agent for the treatment of malignant glioma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research